Tracking Part D Prices Around Generic Entry
An independent published methods example aligning Part D drug markets around generic entry while distinguishing retail from net prices.
Home / UpEvidence / Tracking Part D Prices Around Generic Entry
Source published October 5, 2026 · Resource reviewed October 8, 2026
The research question
How do drug prices and spending evolve around first generic entry?
Data files and cohort construction
The authors combined 100% Medicare prescription drug events (PDE), 2010–2024, with drug classifications and confidential manufacturer rebates. They followed 271 compounds with first generic entry in 2011–2023, pooling formulations and manufacturers. Authorized generics were distinguished using application information.
Measures and analytic design
Quantities became 30-day equivalents. Brand net prices subtracted rebates and coverage-gap discounts; generic and authorized-generic prices remained retail measures. Markets were aligned to entry, with the preceding year’s brand retail price indexed to 100. Market-share-weighted price, volume, and spending averages tracked up to four years before and after.
Robustness checks and interpretation
The article describes a balanced four-year follow-up sensitivity analysis. Otherwise, later event-time estimates can represent different drug sets. This is descriptive, not a causal estimate of generic entry.
Practical application: keep price definitions visible
The following are FastHSR implementation considerations, not additional procedures claimed for the study. A pharmacy team could use an event-time dashboard to follow substitution after competition begins. Build a versioned product-to-compound crosswalk, retain product type, and label every price field by whose payments it includes. Publish a retail-only analysis if that is what your access permits; do not relabel it as net spending.
Decisions to settle before reuse
Set the market-entry rule before inspecting trends. Decide whether to pool strengths and dosage forms, how to resolve product reclassification, and how to treat partial-year entry. Reconcile days supplied, reversals, missing quantities, and duplicate events before aggregation. Report the number of observed compounds at every time point, alongside a fixed-follow-up comparison.
Limitations and local application
PDE alone cannot reproduce confidential net prices. Other post-sale payments are not fully captured; retail and net series should not be treated as interchangeable. For a local application, changes in formulary coverage, membership, dispensing channels, and treatment mix deserve separate attention. Show absolute amounts beside an index: an index makes trajectories comparable but hides the size of each market. Use separate price and quantity displays before attributing a spending change to either component.
Source article and supplement
Laughery S, Baker C, Fehr R. Net Prescription Drug Prices And Spending In Medicare Part D Before And After Generic Entry. Health Affairs. 2026;45(10):1112–1116. doi:10.1377/hlthaff.2026.00257.
The full article and journal appendix link were reviewed on October 8, 2026. The appendix download returned a publisher cookie error and was not independently read. Confirm detailed classifications and sensitivity specifications before replication.
Frequently asked question
Can ordinary Part D claims establish manufacturer net prices?
No. A retail claims amount does not reveal confidential manufacturer rebates. A net-price analysis requires the relevant rebate data and a clearly defined accounting boundary.